A Nationwide Central Diagnosis for Pediatric CNS Tumors in Japan: The JCCG Brain Tumor and Pathology Committees
Open Access
- 25 April 2026
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (7) , 1975-1984
Abstract
In 2016, the Japan Children's Cancer Group launched a nationwide research initiative to provide central diagnosis incorporating pathology review and molecular profiling for pediatric central nervous system (CNS) tumors. Over the first eight years, 2224 cases were registered. Non–next‐generation sequencing analyzes, such as pyrosequencing and NanoString, were routinely performed, mainly for glioma, medulloblastoma, and ependymoma. Additional analyzes, including methylation profiling and RNA sequencing, were conducted for selected diagnostically challenging cases. The most common diagnoses were low‐grade glioma (26%), medulloblastoma (18%), germ cell tumor (16%), high‐grade glioma (12%), and ependymoma (11%). Diagnostic or targetable alterations were detected in nearly half of the glioma samples. Among medulloblastomas, Group 4 was the most prevalent subgroup (48%), followed by SHH‐activated (28%), Group 3 (14%), and WNT‐activated (11%). Among ependymomas, 95% of posterior fossa ependymomas were classified as PFA, and 72% of supratentorial ependymomas were positive for ZFTA fusion. Methylation‐based classification enabled diagnostic refinement and identification of recently recognized novel subtypes. The integration of histopathological review by central pathologists and detailed molecular analyzes facilitated the recognition of rare tumors not yet defined in the World Health Organization classification. Our experience underscores the value of integrated diagnosis, which is now regarded as standard practice for pediatric CNS tumors, and highlights the urgent need for a sustainable clinical framework that incorporates molecular testing. This report represents the first comprehensive overview of the pediatric CNS tumor landscape in Japan in the molecular era.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP19ck0106330)
- Japan Agency for Medical Research and Development (JP20ck0106608)
- Japan Agency for Medical Research and Development (JP21ck0106608)
- Japan Agency for Medical Research and Development (JP23ck0106760)
- Japan Agency for Medical Research and Development (JP24ck0106856)
- Japan Agency for Medical Research and Development (JP16ck0106069)
- Japan Agency for Medical Research and Development (JP17ck0106330)
- Japan Agency for Medical Research and Development (JP18ck0106330)
- Japan Agency for Medical Research and Development (JP21ck0106692)
- Japan Agency for Medical Research and Development (JP22ama221415)
- Japan Agency for Medical Research and Development (JP22ck0106608)
- Japan Agency for Medical Research and Development (JP22ck0106692)
- Japan Agency for Medical Research and Development (JP22ck0106760)
- Japan Agency for Medical Research and Development (JP23ck0106856)
- Japan Agency for Medical Research and Development (JP23ck0106876)
- Japan Agency for Medical Research and Development (JP23ck0106898)
- Japan Agency for Medical Research and Development (JP23ck0106903)
- Japan Agency for Medical Research and Development (JP24ck0106760)
- Japan Agency for Medical Research and Development (JP24ck0106876)
- Japan Agency for Medical Research and Development (JP24ck0106898)
- Japan Agency for Medical Research and Development (JP25ck0106040)
- Japan Agency for Medical Research and Development (JP25ck0106856)
- Japan Agency for Medical Research and Development (JP25ck0106876)
- Japan Agency for Medical Research and Development (JP25ck0106898)
- Japan Society for the Promotion of Science (20K16873)
- Japan Society for the Promotion of Science (25H01070)
This publication has 40 references indexed in Scilit:
- Comprehensive Genome Analysis Facilitates the Diagnosis of Ependymoma With ZFTA::NCOA2 FusionPediatric Blood & Cancer, 2025
- Subependymal giant cell astrocytoma harboring a PRRC2B‐ALK fusion: A case reportPediatric Blood & Cancer, 2019
- High-grade glioneuronal tumor with an ARHGEF2–NTRK1 fusion geneBrain Tumor Pathology, 2019
- Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnosticCancer, 2018
- Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceActa Neuropathologica, 2018
- Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomeActa Neuropathologica, 2017
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variantsActa Neuropathologica, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samplesActa Neuropathologica, 2011